Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias

Published:2004-05-15 Issue:10 Volume:10 Page:3371-3376
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Cortes Jorge,Thomas Deborah,Koller Charles,Giles Francis,Estey Elihu,Faderl Stefan,Garcia-Manero Guillermo,McConkey David,Patel Gira,Guerciolini Roberto,Wright John,Kantarjian Hagop

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 178 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment for a B-cell acute lymphoblastic leukemia patient carrying a rare TP53 c.C275T mutation: A case report;Frontiers in Oncology;2023-01-31

2. Interaction of Bortezomib with Cell Membranes Regulates Its Toxicity and Resistance to Therapy;Membranes;2022-08-23

3. Monoclonal Antibody-Based Treatment and Other New Agents for B-Lineage Acute Lymphoblastic Leukemia;Clinical Management of Acute Lymphoblastic Leukemia;2022

4. The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia;Frontiers in Oncology;2021-12-23

5. Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling;Cell Death & Disease;2021-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP